Analysts Predict 11% Growth Potential for FNX
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 25 2025
0mins
Should l Buy CORT?
Source: NASDAQ.COM
ETF Analysis: The First Trust Mid Cap Core AlphaDEX Fund ETF (FNX) has an implied analyst target price of $138.87, indicating an 11.05% upside from its current trading price of $125.05.
Notable Holdings: Key underlying holdings with significant upside potential include Corcept Therapeutics (61.32% upside), SM Energy (44.95% upside), and Badger Meter (37.97% upside) based on their respective analyst target prices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 33.820
Low
50.00
Averages
91.00
High
121.00
Current: 33.820
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept's Cancer Therapy Receives FDA Approval
- FDA Approval: Corcept Therapeutics' cancer therapy, relacorilant, has received FDA approval as a late-line treatment option in combination with chemotherapy nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Results: The approval is based on data from the company's Phase 3 ROSELLA and Phase 2 trials, which demonstrated that patients receiving relacorilant plus nab-paclitaxel experienced improved progression-free and overall survival compared to those receiving nab-paclitaxel monotherapy, further validating its clinical efficacy.
- Positive Market Reaction: Following the FDA approval announcement, Corcept's shares surged in early trading, reflecting strong investor confidence in the market potential of the drug, which could drive future revenue growth for the company.
- Future Outlook: With FDA approval secured, Corcept is expected to report its Q4 2025 earnings, and investor expectations for its future performance will likely be positively influenced by the drug's market entry, enhancing market interest in its stock.
See More
Corcept Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the securities class action against Corcept if they purchased shares between October 31, 2024, and December 30, 2025, indicating potential economic losses for affected investors.
- Allegations: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding the likelihood of FDA approval for their new drug application, misleading investors about the company's prospects.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 on December 30 to $34.80, reflecting extreme market pessimism regarding the company's future following the FDA's Complete Response Letter.
- Legal Context: The case is pending in the Northern District of California, with the plaintiff being the Allegheny County Employees' Retirement System, highlighting investor concerns over corporate transparency and compliance, which may impact future investor confidence.
See More
Corcept Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: A class action lawsuit has been filed on behalf of investors who purchased Corcept securities between October 31, 2024, and December 30, 2025, alleging that the company made false statements regarding the efficacy of clinical trials supporting its New Drug Application, resulting in investor losses.
- FDA Response: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter citing insufficient clinical evidence for relacorilant's efficacy, causing the stock price to plummet by 50.4% in one day, from $70.20 to $34.80.
- Subsequent Impact: On January 30, 2026, the FDA's redacted CRL further detailed concerns about the relacorilant NDA, leading to an additional 10.6% drop in stock price from $44.61 to $39.87, reflecting market pessimism about the company's future.
- Investor Action: Investors must apply by April 21, 2026, to be appointed as lead plaintiffs, allowing them to represent the class's interests and influence litigation strategy and settlement decisions, highlighting the critical role of investors in legal proceedings.
See More
Lawsuit Claims Management Concealed FDA Warnings on Data Issues
- Lawsuit Background: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff status in the securities class action is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- Information Discrepancy: The lawsuit alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, Relacorilant, by failing to disclose FDA warnings communicated privately, which could lead to significant investor losses.
- Legal Proceedings: Filed in the U.S. District Court for the Northern District of California, the action seeks to recover losses for all individuals and entities who purchased Corcept common stock during the Class Period, highlighting serious deficiencies in the company's transparency.
- Whistleblower Program: Hagens Berman encourages whistleblowers with non-public information about Corcept to assist in the investigation, as the new SEC Whistleblower program offers rewards of up to 30% of any successful recovery, further promoting corporate accountability.
See More
Kyndryl and Others Face Class Action Lawsuits
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. faces allegations of materially false statements regarding its financial reports from August 1, 2024, to February 9, 2026, which could mislead investors about the company's prospects, potentially impacting stock prices and investor confidence.
- PayPal Legal Issues: PayPal Holdings, Inc. is accused of failing to effectively execute its business initiatives between February 25, 2025, and February 2, 2026, which may undermine investor confidence in its competitive position, leading to stock price volatility.
- NuScale Risk Disclosure: NuScale Power Corporation is alleged to have failed to disclose significant risks to its commercialization strategy from May 13, 2025, to November 6, 2025, which could weaken investor confidence in its future growth prospects.
- Corcept Regulatory Challenges: Corcept Therapeutics Incorporated faces allegations of not disclosing FDA concerns regarding the effectiveness assessment of its drug from October 31, 2024, to January 30, 2026, potentially affecting its stock price and market performance.
See More
Corcept Therapeutics Shareholder Notice Issued
- Shareholder Notice Issued: The Gross Law Firm has issued a notice to shareholders of Corcept Therapeutics (NASDAQ:CORT), encouraging those who purchased shares during the class period from October 31, 2024, to December 30, 2025, to contact the firm regarding potential lead plaintiff appointment.
- Allegations of False Statements: The filed complaint alleges that Corcept made false statements regarding its interactions with the FDA, concealing concerns about the adequacy of the relacorilant program, which could lead to significant issues upon NDA submission.
- Deadline for Registration: Shareholders must register by April 21, 2026, to participate in the class action, and failure to do so may affect their rights, prompting the firm to advise prompt action to safeguard their interests.
- Law Firm's Reputation: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to deceit and illegal business practices, emphasizing the importance of responsible corporate conduct.
See More
Corcept's Cancer Therapy Receives FDA Approval
- FDA Approval: Corcept Therapeutics' cancer therapy, relacorilant, has received FDA approval as a late-line treatment option in combination with chemotherapy nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Results: The approval is based on data from the company's Phase 3 ROSELLA and Phase 2 trials, which demonstrated that patients receiving relacorilant plus nab-paclitaxel experienced improved progression-free and overall survival compared to those receiving nab-paclitaxel monotherapy, further validating its clinical efficacy.
- Positive Market Reaction: Following the FDA approval announcement, Corcept's shares surged in early trading, reflecting strong investor confidence in the market potential of the drug, which could drive future revenue growth for the company.
- Future Outlook: With FDA approval secured, Corcept is expected to report its Q4 2025 earnings, and investor expectations for its future performance will likely be positively influenced by the drug's market entry, enhancing market interest in its stock.
See More
Corcept Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the securities class action against Corcept if they purchased shares between October 31, 2024, and December 30, 2025, indicating potential economic losses for affected investors.
- Allegations: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding the likelihood of FDA approval for their new drug application, misleading investors about the company's prospects.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 on December 30 to $34.80, reflecting extreme market pessimism regarding the company's future following the FDA's Complete Response Letter.
- Legal Context: The case is pending in the Northern District of California, with the plaintiff being the Allegheny County Employees' Retirement System, highlighting investor concerns over corporate transparency and compliance, which may impact future investor confidence.
See More
Corcept Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: A class action lawsuit has been filed on behalf of investors who purchased Corcept securities between October 31, 2024, and December 30, 2025, alleging that the company made false statements regarding the efficacy of clinical trials supporting its New Drug Application, resulting in investor losses.
- FDA Response: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter citing insufficient clinical evidence for relacorilant's efficacy, causing the stock price to plummet by 50.4% in one day, from $70.20 to $34.80.
- Subsequent Impact: On January 30, 2026, the FDA's redacted CRL further detailed concerns about the relacorilant NDA, leading to an additional 10.6% drop in stock price from $44.61 to $39.87, reflecting market pessimism about the company's future.
- Investor Action: Investors must apply by April 21, 2026, to be appointed as lead plaintiffs, allowing them to represent the class's interests and influence litigation strategy and settlement decisions, highlighting the critical role of investors in legal proceedings.
See More
Lawsuit Claims Management Concealed FDA Warnings on Data Issues
- Lawsuit Background: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff status in the securities class action is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- Information Discrepancy: The lawsuit alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, Relacorilant, by failing to disclose FDA warnings communicated privately, which could lead to significant investor losses.
- Legal Proceedings: Filed in the U.S. District Court for the Northern District of California, the action seeks to recover losses for all individuals and entities who purchased Corcept common stock during the Class Period, highlighting serious deficiencies in the company's transparency.
- Whistleblower Program: Hagens Berman encourages whistleblowers with non-public information about Corcept to assist in the investigation, as the new SEC Whistleblower program offers rewards of up to 30% of any successful recovery, further promoting corporate accountability.
See More
Kyndryl and Others Face Class Action Lawsuits
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. faces allegations of materially false statements regarding its financial reports from August 1, 2024, to February 9, 2026, which could mislead investors about the company's prospects, potentially impacting stock prices and investor confidence.
- PayPal Legal Issues: PayPal Holdings, Inc. is accused of failing to effectively execute its business initiatives between February 25, 2025, and February 2, 2026, which may undermine investor confidence in its competitive position, leading to stock price volatility.
- NuScale Risk Disclosure: NuScale Power Corporation is alleged to have failed to disclose significant risks to its commercialization strategy from May 13, 2025, to November 6, 2025, which could weaken investor confidence in its future growth prospects.
- Corcept Regulatory Challenges: Corcept Therapeutics Incorporated faces allegations of not disclosing FDA concerns regarding the effectiveness assessment of its drug from October 31, 2024, to January 30, 2026, potentially affecting its stock price and market performance.
See More
Corcept Therapeutics Shareholder Notice Issued
- Shareholder Notice Issued: The Gross Law Firm has issued a notice to shareholders of Corcept Therapeutics (NASDAQ:CORT), encouraging those who purchased shares during the class period from October 31, 2024, to December 30, 2025, to contact the firm regarding potential lead plaintiff appointment.
- Allegations of False Statements: The filed complaint alleges that Corcept made false statements regarding its interactions with the FDA, concealing concerns about the adequacy of the relacorilant program, which could lead to significant issues upon NDA submission.
- Deadline for Registration: Shareholders must register by April 21, 2026, to participate in the class action, and failure to do so may affect their rights, prompting the firm to advise prompt action to safeguard their interests.
- Law Firm's Reputation: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to deceit and illegal business practices, emphasizing the importance of responsible corporate conduct.
See More
